Back to Newsroom

Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board

DOYLESTOWN, Pa., November 18, 2014 – Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced that Brian F. Daniels, M.D., was appointed to its Scientific Advisory Board (SAB).

“We are thrilled to have Brian join our SAB,” said Christian S. Schade, Chief Executive Officer of Novira.  “Brian brings a wealth of clinical development experience which will be invaluable to Novira as our lead core inhibitor program, NVR 3-778, advances through ongoing Phase 1b clinical studies for chronic HBV infection.”

Click here to read more